Short-term efficacy and safety of hyaluronic acid injection for plantar fasciopathy

Tsukasa Kumai, Norihiro Samoto, Atsushi Hasegawa, Hideo Noguchi, Atsushi Shiranita, Masaharu Shiraishi, Satoshi Ikeda, Kazuya Sugimoto, Yasuhito Tanaka, Yoshinori Takakura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: Plantar fasciopathy is the most common cause of plantar heel pain and is considered to be a type of enthesopathy. The short-term efficacy, safety, and dose-response relationship of high-molecular-weight hyaluronic acid (HA) was investigated in patients with plantar fasciopathy. Methods: In this multicenter, prospective, randomized, double-blind, placebo-controlled trial, 168 patients with persistent pain from plantar fasciopathy for more than 12 weeks were randomly assigned to receive 2.5 mL of 1% HA (H-HA), 0.8 mL of 1% HA (L-HA), or 2.5 mL of 0.01% HA (control group) once a week for 5 weeks. The primary endpoint was improvement in visual analogue scale (VAS) score for pain from baseline to week 5. Results: The VAS scores (least squares mean ± standard error) in each group decreased gradually after the start of treatment, a change of −3.3 ± 0.3 cm for the H-HA group, −2.6 ± 0.3 cm for the L-HA group, and −2.4 ± 0.3 cm for the control group, with the H-HA group improving significantly more than the control group (P = 0.029). No serious adverse events were reported. There was no difference between the groups in the incidence rates of adverse drug reactions. Conclusion: The administration of five injections of high-molecular-weight HA is an effective treatment with no serious adverse drug reactions and is a conservative treatment option for plantar fasciopathy. This treatment contributed to alleviation of pain in patients with plantar fasciopathy and improvement in their activities of daily living. Level of evidence: I.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalKnee Surgery, Sports Traumatology, Arthroscopy
DOIs
Publication statusAccepted/In press - 2017 Mar 2
Externally publishedYes

Fingerprint

Hyaluronic Acid
Safety
Injections
Drug-Related Side Effects and Adverse Reactions
Pain
Control Groups
Molecular Weight
Heel
Pain Measurement
Activities of Daily Living
Least-Squares Analysis
Visual Analog Scale
Therapeutics
Placebos
Incidence

Keywords

  • Double-blind
  • Enthesopathy
  • Heel pain
  • Hyaluronic acid
  • Plantar fascia
  • Randomized controlled trial

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Short-term efficacy and safety of hyaluronic acid injection for plantar fasciopathy. / Kumai, Tsukasa; Samoto, Norihiro; Hasegawa, Atsushi; Noguchi, Hideo; Shiranita, Atsushi; Shiraishi, Masaharu; Ikeda, Satoshi; Sugimoto, Kazuya; Tanaka, Yasuhito; Takakura, Yoshinori.

In: Knee Surgery, Sports Traumatology, Arthroscopy, 02.03.2017, p. 1-9.

Research output: Contribution to journalArticle

Kumai, T, Samoto, N, Hasegawa, A, Noguchi, H, Shiranita, A, Shiraishi, M, Ikeda, S, Sugimoto, K, Tanaka, Y & Takakura, Y 2017, 'Short-term efficacy and safety of hyaluronic acid injection for plantar fasciopathy', Knee Surgery, Sports Traumatology, Arthroscopy, pp. 1-9. https://doi.org/10.1007/s00167-017-4467-0
Kumai, Tsukasa ; Samoto, Norihiro ; Hasegawa, Atsushi ; Noguchi, Hideo ; Shiranita, Atsushi ; Shiraishi, Masaharu ; Ikeda, Satoshi ; Sugimoto, Kazuya ; Tanaka, Yasuhito ; Takakura, Yoshinori. / Short-term efficacy and safety of hyaluronic acid injection for plantar fasciopathy. In: Knee Surgery, Sports Traumatology, Arthroscopy. 2017 ; pp. 1-9.
@article{5f3e2d344cce483ba9d9a4f9e7ddf73d,
title = "Short-term efficacy and safety of hyaluronic acid injection for plantar fasciopathy",
abstract = "Purpose: Plantar fasciopathy is the most common cause of plantar heel pain and is considered to be a type of enthesopathy. The short-term efficacy, safety, and dose-response relationship of high-molecular-weight hyaluronic acid (HA) was investigated in patients with plantar fasciopathy. Methods: In this multicenter, prospective, randomized, double-blind, placebo-controlled trial, 168 patients with persistent pain from plantar fasciopathy for more than 12 weeks were randomly assigned to receive 2.5 mL of 1{\%} HA (H-HA), 0.8 mL of 1{\%} HA (L-HA), or 2.5 mL of 0.01{\%} HA (control group) once a week for 5 weeks. The primary endpoint was improvement in visual analogue scale (VAS) score for pain from baseline to week 5. Results: The VAS scores (least squares mean ± standard error) in each group decreased gradually after the start of treatment, a change of −3.3 ± 0.3 cm for the H-HA group, −2.6 ± 0.3 cm for the L-HA group, and −2.4 ± 0.3 cm for the control group, with the H-HA group improving significantly more than the control group (P = 0.029). No serious adverse events were reported. There was no difference between the groups in the incidence rates of adverse drug reactions. Conclusion: The administration of five injections of high-molecular-weight HA is an effective treatment with no serious adverse drug reactions and is a conservative treatment option for plantar fasciopathy. This treatment contributed to alleviation of pain in patients with plantar fasciopathy and improvement in their activities of daily living. Level of evidence: I.",
keywords = "Double-blind, Enthesopathy, Heel pain, Hyaluronic acid, Plantar fascia, Randomized controlled trial",
author = "Tsukasa Kumai and Norihiro Samoto and Atsushi Hasegawa and Hideo Noguchi and Atsushi Shiranita and Masaharu Shiraishi and Satoshi Ikeda and Kazuya Sugimoto and Yasuhito Tanaka and Yoshinori Takakura",
year = "2017",
month = "3",
day = "2",
doi = "10.1007/s00167-017-4467-0",
language = "English",
pages = "1--9",
journal = "Knee Surgery, Sports Traumatology, Arthroscopy",
issn = "0942-2056",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Short-term efficacy and safety of hyaluronic acid injection for plantar fasciopathy

AU - Kumai, Tsukasa

AU - Samoto, Norihiro

AU - Hasegawa, Atsushi

AU - Noguchi, Hideo

AU - Shiranita, Atsushi

AU - Shiraishi, Masaharu

AU - Ikeda, Satoshi

AU - Sugimoto, Kazuya

AU - Tanaka, Yasuhito

AU - Takakura, Yoshinori

PY - 2017/3/2

Y1 - 2017/3/2

N2 - Purpose: Plantar fasciopathy is the most common cause of plantar heel pain and is considered to be a type of enthesopathy. The short-term efficacy, safety, and dose-response relationship of high-molecular-weight hyaluronic acid (HA) was investigated in patients with plantar fasciopathy. Methods: In this multicenter, prospective, randomized, double-blind, placebo-controlled trial, 168 patients with persistent pain from plantar fasciopathy for more than 12 weeks were randomly assigned to receive 2.5 mL of 1% HA (H-HA), 0.8 mL of 1% HA (L-HA), or 2.5 mL of 0.01% HA (control group) once a week for 5 weeks. The primary endpoint was improvement in visual analogue scale (VAS) score for pain from baseline to week 5. Results: The VAS scores (least squares mean ± standard error) in each group decreased gradually after the start of treatment, a change of −3.3 ± 0.3 cm for the H-HA group, −2.6 ± 0.3 cm for the L-HA group, and −2.4 ± 0.3 cm for the control group, with the H-HA group improving significantly more than the control group (P = 0.029). No serious adverse events were reported. There was no difference between the groups in the incidence rates of adverse drug reactions. Conclusion: The administration of five injections of high-molecular-weight HA is an effective treatment with no serious adverse drug reactions and is a conservative treatment option for plantar fasciopathy. This treatment contributed to alleviation of pain in patients with plantar fasciopathy and improvement in their activities of daily living. Level of evidence: I.

AB - Purpose: Plantar fasciopathy is the most common cause of plantar heel pain and is considered to be a type of enthesopathy. The short-term efficacy, safety, and dose-response relationship of high-molecular-weight hyaluronic acid (HA) was investigated in patients with plantar fasciopathy. Methods: In this multicenter, prospective, randomized, double-blind, placebo-controlled trial, 168 patients with persistent pain from plantar fasciopathy for more than 12 weeks were randomly assigned to receive 2.5 mL of 1% HA (H-HA), 0.8 mL of 1% HA (L-HA), or 2.5 mL of 0.01% HA (control group) once a week for 5 weeks. The primary endpoint was improvement in visual analogue scale (VAS) score for pain from baseline to week 5. Results: The VAS scores (least squares mean ± standard error) in each group decreased gradually after the start of treatment, a change of −3.3 ± 0.3 cm for the H-HA group, −2.6 ± 0.3 cm for the L-HA group, and −2.4 ± 0.3 cm for the control group, with the H-HA group improving significantly more than the control group (P = 0.029). No serious adverse events were reported. There was no difference between the groups in the incidence rates of adverse drug reactions. Conclusion: The administration of five injections of high-molecular-weight HA is an effective treatment with no serious adverse drug reactions and is a conservative treatment option for plantar fasciopathy. This treatment contributed to alleviation of pain in patients with plantar fasciopathy and improvement in their activities of daily living. Level of evidence: I.

KW - Double-blind

KW - Enthesopathy

KW - Heel pain

KW - Hyaluronic acid

KW - Plantar fascia

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=85014077632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014077632&partnerID=8YFLogxK

U2 - 10.1007/s00167-017-4467-0

DO - 10.1007/s00167-017-4467-0

M3 - Article

C2 - 28255655

AN - SCOPUS:85014077632

SP - 1

EP - 9

JO - Knee Surgery, Sports Traumatology, Arthroscopy

JF - Knee Surgery, Sports Traumatology, Arthroscopy

SN - 0942-2056

ER -